Emicizumab is the first non-replacement agent licensed for prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A, regardless of the presence of anti-FVIII inhibitors. This evidence concerns the gene F8 and hemophilia A.